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METHODS FOR INCREASING LEPTIN
LEVELS USING NICOTINIC ACID
COMPOUNDS

also appears to trigger apoptosis in White adipose tissue.
Most of the molecule’s metabolic effects appear to result

from speci?c interactions With receptors located in the
central nervous system, and in peripheral tissues. The recep
tor has been identi?ed and is a Class I cytokine receptor that
belongs to a family that includes the IL-2 receptor, interferon

RELATED APPLICATION

This application claims priority of provisional application
No. 60/274,349, ?led Mar. 8, 2001, incorporated by refer

receptor and groWth hormone receptor. In brief, the leptin
receptor transmits leptin signal to the three STAT molecules
STAT 3, 5, and 6, referred to collectively as the “fat

ence.

FIELD OF THE INVENTION

10

STATS.”

The accepted vieW of leptin is that its primary role is to
The invention relates to the use of niacin derivatives and

prevent obesity via regulating food intake and thermogen

niacin in the regulation of leptin modulated pathWays.

esis via action on hypothalomic centers. Recent evidence

Speci?cally, niacin and its derivatives, such as nicotinate

suggests, hoWever, that leptin may have an additional role,
i.e., it may exhibit antisteatotic activity, in that fatty acid
over-accumulation in non-adipose tissue may be prevented

esters, lauryl nicotinate ester in particular, stimulate produc

15

tion of leptin, With rami?cations as discussed infra.

by leptin mediated regulation of [3-oxidation. Leptin

BACKGROUND AND PRIOR ART

increases enZymes involved in fatty acid oxidation and
stimulates a previously unobserved form of lipolysis, Where

Leptin, a 167 amino acid protein encoded by the ob gene,
Was identi?ed in the course of research in identifying

glycerol is released Without proportional release of free fatty

molecular defects in an obesity prone strain, i.e., the “ob/ob”
mouse. It has been found that leptin is produced for the most
part in White adipose tissue, With very small amounts being
found in broWn adipose tissue. Exemplary of the patent

acids.

literature relating to this molecule are US. Pat. Nos. 6,132,

Various leptin receptor isoforms are expressed throughout
the body suggesting that leptin has additional physiological
functions on extra-neural tissue. Studies have been carried
25

909, all of Which are incorporated by reference.

metabolism, as Well as expression of some enZymes. If a

direct effect of leptin on a given tissue is observed, it implies

The ?rst reports on leptin suggested that it Was an

adipocyte derived, signaling molecule, Which limited food
intake and increased energy expenditure, i.e., an “adiposat.”
The evidence supporting this included observed decreases in
body Weight, and improved metabolic control in rodents that
evidenced genetic or diet induced obesity that Were injected
With leptin. In the case of ob/ob mice, Which have mutations
in the ob gene, leading to synthesis of defective leptin
molecules that are degraded intracellularly, the effect of
leptin is especially pronounced. The ob/ob mice are obese,
diabetic and sterile, and exhibit reduced activity,

metabolism, and body temperature. In addition, leptin
de?cient ob/ob mice suffer from seriously delayed Wound
healing. Systemic or topically administered leptin has been
shoWn to improve re-epitheliaZation of Wounds in this
model. See Frank, et al., J. Clin. Invest. 106: 501—509
(2000). As such, the ob/ob mouse has been used as a model

system for testing drugs for their ability to reverse impaired

30

35

(i) Leptin activates STAT 3, and increases PPARO. activ

ity;
40

cells;
(iv) PPARO. activators inhibit mouse skin tumor promo
tion.
45

type mice. In addition, STAT 3 and peroxisome-proliferator
activated receptor (“PPAR” hereafter), Which are the doWn
stream regulators in the leptin pathWay, are involved in skin
homeostasis. See Komuvres, et al., J Invest. Dermatol

See, eg Bendinelli, et al., Mol. Cell Endocrin 168:11—20
(2000); Unger, et al., Proc. Natl. Acad. Sci USA
96:2327—2332 (1992); Peters, et al., J. Biol. Chem.
272:27307—27312 (1997); Hanley, et al., J. Clin. Invest.
100:705—712 (1997); Sano, et al., EMBOJ 18:4657—4666

(1999); Thuillier, et al., Mol. Carcin 29:134—142 (2000).
In addition to playing a role in energy regulation, leptin
also regulates endocrine and immune functions. Leptin
levels increase acutely during infection and in?ammation,

115:361—267 (2000). STAT 3 has been shoWn to play an
55

and may represent a protective component of the host
response to in?ammation. Leptin de?ciency increases sus
ceptibility to infectious and in?ammatory stimuli and is

associated With dysregulation of cytokine production. See
Faggioni, et al., FASEB J. 15:2565—2571 (2001).
In addition, it can be hypothesiZed that the pathWay
60

described supra can also lead to skin homeostasis and

65

remodeling, Which in turn leads to epidermal barrier
development, Wound healing, and hair groWth, as Well as the
inhibition of skin tumor promotion caused by increased
immune functions. This is summariZed in FIG. 1.
Niacin is essential to formation of the coenZymes nicoti

PPARO. activators inhibit murine skin tumor promotion. This
is consistent With PPARO. having a role in skin physiology.

See Thuillier, et al., Mol. Carcinogenesis 29:134—142

(2000).
Further research on leptin has revealed that the molecule

(ii) PPARot/PPRE induces apo A-I expression in liver
(iii) STAT3/PPARO. is essential for skin homeostasis;

In addition to the effect on leptin de?cient mice, discussed

alters the transcription of several adipose speci?c genes
involved in lipogenesis, lipolysis, and energy metabolism. It

STAT 3 in adipose tissue, binding of leptin to its receptor
leads to receptor oligomeriZation, and JAK activation, lead
ing in turn to STAT phosphorylation; phosphorylated STATS
dimeriZe and translocate into nuclei, Where they activate
target genes. In brief:

supra, leptin markedly promoted re-epitheliaZation in Wild

activators normaliZe cell proliferation, including epidermal
differentiation, and accelerate the development of the epi
dermal permeability barrier. See Hanley, et al., J. Clin Inv.
100:705—712 (1997). Recently, it has been demonstrated that

rapid induction of signal transduction mechanisms, ?oWing
from hormone/receptor binding. Essentially the mechanism
of action can be summariZed as folloWs: leptin activates

Wound healing.

essential role in skin remodeling, including hair follicle
cycling and Wound healing. It is also knoWn that PPARO.

out to evaluate tissue responsiveness to leptin, via determin

ing What effects, if any, it has on glucidic and lipidic

724; 6,124,448; 6,124,439; 6,068,976; 6,048,837 and 5,795,

namide dinucleotide (NAD), and NAD phosphate (NADP),
Where the nicotinamide moiety acts as an electron acceptor

US 6,750,234 B2
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3
or hydrogen donor in many biological redox reactions. To

After 24 hours, the culture medium Was analyZed for

elaborate, NAD functions as an electron carrier for intrac
ellular respiration, and as a coenZyme in the oxidation of
fuel molecules. NADP acts as a hydrogen donor in reductive

leptin, using a commercially available ELISA kit.
The results, Which are presented in FIG. 2, shoW that in
the cultures to Which niacin Was added, leptin production

biosynthesis, including fatty acid and steroid synthesis. As is

increased 62%.

the case With NAD, it also acts as a coenZyme.

NAD is the substrate for three classes of enZymes that
transfer ADP-ribose units to proteins involved in DNA

repair, cell differentiation, and cellular calcium mobiliZation.
Nicotinic acid, in contrast to nicotinamide, When given in
doses of 1.5—4 g/day improves blood cholesterol pro?les.
Acipimox, a commercially available, nicotinic acid ana
log and hypolipodemic agent, Was shoWn to increase plasma
leptin levels in transgenic mice. See, e.g., Worm, et al., Eur.
J. Endocrin 143:389—395 (2000).

EXAMPLE 2

Female apoB/CETP double transgenic mice, obtained
10

15

It has been shoWn that nicotinic acid derivatives have

consumption and Was approximately 1400 mg/kg of body
20

including a dodecyl, or lauryl nicotinic acid ester. It has noW
been found that such nicotinic acid esters, such as lauryl
nicotinic acid ester, stimulate leptin production to an extent
25

provided.
30

believed to operate in the invention. Note a ?at line means

mercially available murine leptin radioimmunoassay. The
35

ester.
40

The experiments described in example 2 Were continued,

in the experiment described in this example. Speci?cally,
45

FIG. 6 sets forth parallel results, in Which the serum leptin

supra, or myristyl nicotinate ester lotion, in varying concen
trations. Controls received vehicle only. The lotion Was
applied at a dose of 4 ml/kg/mouse.
Serum leptin levels Were measured, as described, supra.
The results indicate that the serum leptin levels increased by

DETAILED DESCRIPTION OF PREFERRED
EMBODIMENTS
EXAMPLE 1
55

45% in the subject animals Which received the 10% lauryl
nicotinate ester lotion, While the increase for subject animals
Which received myristyl nicotinateesterWas 57% (for the 2%

formulation), and 77% (for the 5% formulation). FIG. 4
presents these results.

adipocytes.

treatment. The preadipocytes Were plated, and alloWed to

male BALB/C mice Were shaved, from the scapulae to tail

bases. The subject animals then received topical application
of the lauryl nicotinate ester lotion, described in example 2,

levels of the mice Were measured.

from subcutaneous adipose tissue, folloWing collagenase

oral niacin did increase the amount of circulating leptin,
hoWever, the lauryl nicotinate ester surpassed it in terms of
the amount of circulating leptin.
EXAMPLE 3

nicotinic acid esters.

Human adipocytes Were obtained in accordance With
standard methods. In brief, preadipocytes Were collected

RIA Was carried out on fasting (16 h) blood samples
obtained from the retroorbital plexus. The blood samples
Were collected and centrifuged at 2000><g for 15 minutes to
secure plasma. The results, summariZed in FIG. 3, shoW that

niacin Was administered in the form of lauryl nicotinic acid

Adipose tissue is recogniZed as the major source of leptin
production in animals. As such, experiments Were designed
to determine the effect of niacin on leptin production in

is equivalent to a dose from about 0.48 to about 4.8 g/day/70

kg human. The lotion Was applied daily for 13 Weeks.
Leptin levels in plasma Were determined using a com

the target condition is inhibited. Hence, the effect of leptin
on skin tumor promotion is inhibition of the tumor.

FIG. 4 presents a summary of data generated folloWing
the Work of example 2, in Which serum leptin levels Were
measured. “NIA 114” is the lauryl ester, While “NIA 112” is
the myristyl ester.
FIG. 5 summariZes results of experiments designed to
shoW changes in Wound siZe folloWing administration of the

group, backs Were shaved, and the lauryl nicotinate ester
Was applied to shaved areas, via 200 mg of lotion, containing
10% (Wt/Wt) of the lauryl nicotinate ester. The amount of the

ester applied is approximately 80—800 mg/kg, again assum
ing an average Weight of 25 g. Using Freireich, supra, this

BRIEF DESCRIPTION OF THE FIGURES

FIG. 2 summariZes data relating to leptin production in
adipocytes in vitro.
FIG. 3 compares the result of experiments designed to
determine the levels of plasma leptin in test animals, after

Weight, based upon an estimated consumption of 23 ml of
Water per 100 g of body Weight, and an average body Weight
of 25 g. This is equivalent to about 8.4 g/day for a 70 kg
human. See Freireich, et al., Cancer Chemother. Rep. 50:

219—244 (1966) incorporated by reference. For the third

not seen With niacin. As the nicotinic acid esters can be

FIG. 1 is a proposed mechanism and effect pathWay

niacin, in the form of its sodium salt, dissolved in drinking
niacin intake of the animals Was estimated based on Water

See, e.g., US. Pat. No. 6,337,065, ?led Dec. 1, 1999 to

Jacobson, et al., incorporated by reference in its entirety.

formulated as e.g., materials suitable for topical application,
a neW approach to leptin stimulation and production is

Without lauryl nicotinate ester. A second group received

Water at a concentration of 0.75% (0.63% free acid). The

ef?cacy in, inter alia, skin cell protection, DNA repair, etc.
This application describes various nicotinic acid derivatives,

from a commercial supplier, Were divided into 3 groups, and
housed as six animals per cage. One group served as control,
and received a standard diet, Without added niacin. Backs
Were shaved, and lotion Was applied Which Was identical to
the lotion applied to the third group, as described infra,

EXAMPLE 4
60

The association of leptin With Wound healing Was dis
cussed supra. This correlation Was investigated in these

differentiate for 3 Weeks, to form adipocytes.
The adipocytes Were then incubated, in 0.6 ml of DMEM/

experiments.

added. In addition, cultures either received 0.1 mM niacin,

They then received topical application of a 20% nicotinate
ester lotion, every day, for 14 days. The dosing Was 100 pl

Mice Were in?icted With full thickness Wounds of about 6
F-10 medium, to Which 2% bovine serum albumin Was 65 mm in diameter, under anesthesia (sodium phenobarbital).
or did not.

US 6,750,234 B2
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for each application, With tWo applications every day. As a

topical administration. For eXample, in the case of timed
released application, “patches,” such as the type used in
timed release of nicotine, bandages, Wraps, and so forth may

control, the lotion Without the ester Was used. Wound
diameter Was measured every day.
The results are presented in FIG. 5, Which shoWs that the
mice Which received the nicotinate ester containing formu
lations shoWed a reduction of Wound thickness, as composed

be employed.
The nicotinic acid ester is administered in an amount

sufficient to stimulate leptin production. The dose used can
and Will vary; hoWever, formulations should deliver, e.g.,

to controls. The lauryl ester Was most effective With a 43%

reduction.
When the serum leptin levels Were measured, the mice
Which received the nicotinate ester application Were found to

doses ranging from about 0.1 to about 10 g/day/70 kg body
Weight, more preferably from about 0.1 to about 7 g/day/70
10

kg body Weight, most preferably from about 0.4 to about

have an increase of 44% as compared to controls. These
results are depicted in FIG. 6.

5/g/day/70 kg body Weight.

The foregoing eXamples set forth various features of the
invention Which include, inter alia, a method for stimulating
production of leptin in a subject in need thereof, by admin
istering to said subject a leptin stimulating amount of a

can lead, in addition to the effects associated With leptin

As indicated, supra, the stimulation of leptin production
15

previously, to regression of skin tumors, skin homeostases

and remodeling, epidermal barrier development, Wound
healing, and hair groWth.
Other applications Will be clear to the skilled artisan and
need not be elaborated herein.
We claim:

nicotinic acid or nicotinic acid derivative, such as a nicotinic

acid ester. Most preferably, this is a lauryl nicotinic acid
ester, although other compounds, such as those described in

the patent application cited supra may also be used. Espe

1. A method for increasing leptin levels in a subject
suffering from a full thickness Wound comprising adminis
tering to said subject an amount of a nicotinic acid alkyl

cially preferred are nicotinic acid per se, or nicotinic acid

alkyl esters, Where the ester moiety contains from 1—30,
optionally substituted, carbon atoms. More preferably, the
alkyl moiety contains 1—22 carbon atoms, most preferably
1—18 carbon atoms. The subjects are preferably subjects

ester sufficient to increase leptin levels in said subject so as
to reduce thickness of said full thickness Wound, Wherein the
alkyl chain of said nicotinic acid alkyl ester contains from 8

suffering from a condition that can be alleviated by increased

to 22 carbon atoms.

leptin levels, including those set forth in FIG. 1, improved
immune function, skin epitheliation, hair follicle cycling,

contains 12 or 14 carbon atoms.

2. The method of claim 1, Wherein said alkyl chain

inhibition of tumor formation, such as skin tumor formation,

3. The method of claim 1, Wherein said nicotinic acid

and so forth.

alkyl ester is administered orally.
4. The method of claim 1, Wherein said nicotinic acid

The mode by Which the nicotinic acid or ester is admin

istered to the subject may vary. Oral, time release,
intravenous, intradermal, and other forms of administration
are contemplated, as topical administration. Such topical
administration may be via a creme, lotion, liquid, aerosol,
body Wash, mouthWash, toothpaste, gavage, or other form of

alkyl eater is administered topically.
5. The method of claim 1, comprising administering more
35

than one nicotinic acid alkyl ester.

